Eucope Visual

Archives for Newsletter

European health community issues key questions Article 50 negotiations must answer for patients and public health

Thursday, March 8th, 2018 in Brexit Newsletter Press Releases

The European Health Community has warned that time is running out to secure patients’ interests in Brexit negotiations.  With Phase 2 of the negotiations looming, health groups across Europe have drawn up a list of crucial unanswered questions that must be answered by the EU and UK negotiators to ‘put ... read more...

EUCOPE-EURORDIS Press Release on Recommendations on Orphan Medicines Pricing and Reimbursement

Monday, March 13th, 2017 in News Newsletter Press Releases

Expert Group Publishes Recommendations on Orphan Medicines Pricing and Reimbursement Brussels,13th March 2017. Rare diseases are a major public health issue. Despite new legislation to support the authorization of orphan medicinal products to treat rare diseases, many products do not reach patients in time, leading to continued decline in quality ... read more...

EUCOPE, EFPIA and EuropaBio welcome the Publication of the European Commission’s Study on Off-Label Use and call for policy measures that preserve patients’ safety and the integrity of the EU regulatory regime

Thursday, March 2nd, 2017 in News Newsletter Press Releases

The Associations welcome the European Commission’s decision to publish the results of its study on off-label use in the EU as an effort to offer clarity and transparency in relation to this practice. The report provides useful information on the drivers of off-label use. In particular, it acknowledges that, beyond purely ... read more...

EUCOPE Press Release on European Parliament’s adoption of an own-initiative report on Access to Medicines

Thursday, March 2nd, 2017 in News Newsletter Press Releases

Pharmaceutical and biotech SMEs across the EU welcome the adoption of the European Parliament’s Report on Access to Medicines but call for caution Brussels, 2 March – EUCOPE, the voice for European small-to-medium sized innovative companies in the field of pharmaceuticals, biotechnologies and medical devices, welcomes the adoption by the European ... read more...